The FDA has sent three waves of warning letters to telehealth companies marketing compounded GLP-1s since September 2025, most recently 25 letters in June 2026, citing misleading claims that the product is the same as the FDA-approved drug and sellers that never disclose which pharmacy made the medication
Relief strategies include MiraLAX, 25-35g daily fiber, 2-3L water and regular walking achieving 85%+ success rates
Well use lower doses more intelligently, guided by better biomarkers instead of chasing arbitrary weight goals
This dual mechanism often produces more pronounced appetite suppression and potentially greater weight loss compared to semaglutide alone
The injectable medications mimic a hormone made in the gut called glucagon-like peptide-1 (GLP-1), which helps manage blood sugar, reduce appetite and slow stomach emptying so you feel fuller, longer